Patents Assigned to EpiAxis Therapeutics Pty Ltd.
  • Stem cell modulation II
    Patent number: 10736892
    Abstract: Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-?) for inhibiting the growth of PKC-?-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: August 11, 2020
    Assignee: EpiAxis Therapeutics Pty Ltd.
    Inventors: Sudha Rao, Anjurn Zafar
  • Compositions for modulating cancer stem cells and uses therefor
    Patent number: 10485772
    Abstract: Disclosed are compositions and methods for modulating cancer stem cells. More particularly, the present invention discloses the use of lysine demethylase (LSD) inhibitors and protein kinase C theta inhibitors (PKC-?) for inhibiting the growth of LSD- and/or PKC-?-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including non-metastatic and metastatic cancer and/or for preventing cancer recurrence.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: November 26, 2019
    Assignee: EpiAxis Therapeutics Pty Ltd.
    Inventors: Sudha Rao, Anjum Zafar